Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALBENDAZOLE vs ALBENZA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Albendazole inhibits tubulin polymerization by binding to beta-tubulin, disrupting microtubule formation, which leads to impaired glucose uptake and depletion of glycogen stores in susceptible parasites, resulting in their immobilization and death.
Albendazole is a benzimidazole carbamate that inhibits tubulin polymerization by binding to the colchicine site of β-tubulin, disrupting microtubule formation. This leads to impaired uptake of glucose and depletion of glycogen stores, resulting in immobilization and death of susceptible helminths.
Cystic hydatid disease (Echinococcus granulosus),Neurocysticercosis (Taenia solium),Giardiasis (off-label),Cutaneous larva migrans (off-label),Trichuriasis (off-label),Ascariasis (off-label),Hookworm infections (off-label)
FDA-approved: Hydatid disease (Echinococcus granulosus) and neurocysticercosis (Taenia solium).,Off-label: Ascariasis, trichuriasis, hookworm infections, enterobiasis, strongyloidiasis, cutaneous larva migrans, giardiasis, microsporidiosis, and other parasitic infestations.
400 mg orally twice daily for 3-7 days for most indications; for neurocysticercosis, 400 mg orally twice daily for 8-30 days; for hydatid disease, 400 mg orally twice daily for 28-day cycles with 14-day drug-free intervals for 3 cycles.
400 mg orally twice daily for 60 days for neurocysticercosis; 400 mg orally once daily for 3 days for pinworm; 400 mg orally once daily for 3 days for hookworm, roundworm, whipworm; 400 mg orally twice daily for 3 days for tapeworms; 400 mg orally twice daily for 7 days for giardiasis.
Terminal half-life of albendazole sulfoxide is 8–12 hours; parent drug half-life is <1 hour. Clinical context: supports once- or twice-daily dosing.
Terminal elimination half-life of albendazole sulfoxide (active metabolite) is 8-12 hours; albendazole itself has a very short half-life (<1 hour) due to extensive first-pass metabolism.
Primarily hepatic via microsomal enzymes; undergoes oxidation to albendazole sulfoxide (active metabolite) by CYP3A4 and flavin-containing monooxygenases (FMO). Further metabolized to albendazole sulfone (inactive) and other oxidative metabolites.
Primarily metabolized by hepatic microsomal enzymes, specifically to albendazole sulfoxide (active metabolite) via CYP3A4 and possibly other CYP isoforms. Further metabolized to albendazole sulfone (inactive) and other metabolites.
Primarily renal (80%) as inactive metabolites; <2% unchanged in urine. Biliary/fecal excretion accounts for ~20%.
Primarily biliary/fecal (less than 2% renal as unchanged drug and metabolites; most eliminated via bile into feces as metabolites).
70% bound to plasma proteins, primarily albumin.
Albendazole: ~70% bound to plasma proteins (mainly albumin). Albendazole sulfoxide: ~70% bound.
0.2–0.6 L/kg, indicating distribution into tissues; concentrates in liver, bile, and cerebrospinal fluid.
Albendazole sulfoxide: 0.8-1.2 L/kg, indicating extensive tissue distribution including bile and CSF.
Oral bioavailability is low (~5%) due to extensive first-pass metabolism; co-administration with a high-fat meal increases bioavailability up to 4–5-fold.
Oral: Poor bioavailability (~5-10%) of parent drug due to extensive first-pass metabolism; enhanced (up to 5-fold) with high-fat meal. Not administered parenterally.
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (Cr Cl <15 m L/min), use with caution; consider dose reduction or extended intervals. No specific GFR-based guidelines available.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (Cr Cl <30 m L/min); use with caution.
Contraindicated in patients with severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), use with caution; monitor liver function. No specific dose adjustment guidelines available.
Contraindicated in patients with known cirrhosis (Child-Pugh C). For mild to moderate hepatic impairment (Child-Pugh A or B), monitor liver function; dose adjustment not established.
For children >2 years: 15 mg/kg/day orally in 2 divided doses (max 800 mg/day) for most indications. For neurocysticercosis: 15 mg/kg/day orally in 2 divided doses (max 800 mg/day) for 8-30 days. For hydatid disease: 15 mg/kg/day orally in 2 divided doses (max 800 mg/day) for 28-day cycles with 14-day drug-free intervals. For children <2 years: safety and efficacy not established.
For children ≥2 years: 400 mg orally twice daily for 60 days for neurocysticercosis; 400 mg orally once daily for 3 days for pinworm; 400 mg orally once daily for 3 days for hookworm, roundworm, whipworm; 400 mg orally twice daily for 3 days for tapeworms; 400 mg orally twice daily for 7 days for giardiasis. For children <2 years: not recommended.
No specific dose adjustment recommended; use with caution due to potential age-related hepatic or renal impairment. Monitor liver function and blood counts regularly.
No specific dose adjustment recommended; use with caution due to potential hepatic and renal decline. Monitor for adverse effects.
Albendazole may cause fetal harm when administered to pregnant women. It is contraindicated in pregnancy and should not be used in women who are or may become pregnant. Women of childbearing potential should have a negative pregnancy test before starting treatment and should use effective contraception during therapy and for one month after completion.
NOT FDA APPROVED FOR ANY INDICATION IN THE UNITED STATES. (Note: This warning applies as Albendazole is not FDA-approved for use in the US; however, it is marketed elsewhere. In the US, it is available under an investigational protocol or as a compounded product.)
Bone marrow suppression: Monitor CBC at start and periodically; risk of pancytopenia, particularly in patients with hepatic disease or receiving high doses.,Hepatotoxicity: Monitor liver function tests due to risk of elevated transaminases and rare hepatic failure.,Risk of neurocysticercosis exacerbation: May cause increased intracranial pressure or seizures; treat with corticosteroids and anticonvulsants as needed.,Retinal damage: In ocular neurocysticercosis, evaluate for retinal lesions before therapy due to risk of retinal damage from inflammation.,Renal impairment: Use with caution; dose adjustment may be necessary.,Lactation: Excreted in breast milk; caution in nursing mothers.
Bone marrow suppression: Monitor blood counts regularly; risk of agranulocytosis, pancytopenia.,Hepatotoxicity: Elevation of liver enzymes; contraindicated in patients with hepatic disease or abnormal liver function tests.,Neurotoxicity: Risk of seizures, especially in neurocysticercosis due to inflammatory response to dying parasites.,Carcinogenicity: Long-term use associated with increased risk of tumors in animal studies.,Pregnancy: Category D (positive evidence of human fetal risk); avoid use in pregnant women or those likely to become pregnant.
Pregnancy (absolute),Known hypersensitivity to albendazole or any of its components,Patients with pre-existing bone marrow suppression (relative)
Hypersensitivity to albendazole or benzimidazole compounds.,Pregnancy (Category D) and lactation.,Pre-existing hepatic disease or unexplained liver function test abnormalities.,Bone marrow depression or severe neutropenia.
Take with a high-fat meal (≥40 g fat) to significantly increase oral bioavailability. Avoid grapefruit juice as it may affect drug metabolism. No specific dietary restrictions otherwise.
Albendazole absorption is enhanced by fatty foods; a high-fat meal increases plasma concentration of the active metabolite albendazole sulfoxide by up to 5-fold. Avoid grapefruit juice as it may alter metabolism via CYP3A4 inhibition. Fatty meals are recommended to maximize efficacy.
FDA Category C. First trimester: risk of skeletal abnormalities and embryotoxicity based on animal studies. Second and third trimesters: limited human data, but potential for fetal harm; avoid use unless benefit outweighs risk.
Albendazole is contraindicated in pregnancy, especially during the first trimester. It has been shown to be embryotoxic and teratogenic in animals. In humans, there are reports of congenital malformations when used during pregnancy, including craniofacial defects and limb abnormalities. Use is not recommended in women who are or may become pregnant.
Excreted in breast milk; M/P ratio not established. Use with caution, especially in neonates due to risk of bone marrow suppression.
Albendazole is excreted into human breast milk. The milk-to-plasma (M/P) ratio is approximately 0.1. Due to potential adverse effects in nursing infants (e.g., bone marrow suppression, hepatic effects), caution is advised. The manufacturer recommends discontinuing breastfeeding or the drug, taking into account the importance of the drug to the mother.
No specific dose adjustment recommended in pregnancy; pharmacokinetic changes not well studied. Use lowest effective dose and shortest duration possible.
No specific dosing adjustments for pregnancy are established. Use is contraindicated in pregnancy due to teratogenicity. If treatment is necessary, avoid during first trimester and use the lowest effective dose for the shortest duration under strict medical supervision. Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered metabolism) may require therapeutic drug monitoring if available.
Albendazole is a broad-spectrum anthelmintic that inhibits microtubule polymerization by binding to beta-tubulin. It is highly effective against Echinococcus granulosus cysts but requires prolonged therapy (e.g., 28-day cycles). Monitor liver function tests (LFTs) at baseline and every 2 weeks due to risk of hepatotoxicity. For neurocysticercosis, co-administer corticosteroids to reduce inflammatory reaction from cyst degeneration. Albendazole is pregnancy category C; avoid in first trimester and in women planning pregnancy within 1 month of therapy. Absorption is enhanced by a fatty meal; administer with a high-fat meal to increase bioavailability up to 5-fold.
Albendazole is a broad-spectrum anthelmintic effective against intestinal and tissue nematodes, cestodes, and some protozoa. It is poorly absorbed orally; co-administration with a fatty meal significantly increases bioavailability (up to 5-fold). Monitor liver function tests periodically due to risk of hepatotoxicity. Contraindicated in pregnancy (category C) and in patients with known hypersensitivity. For neurocysticercosis, concomitant corticosteroids and antiepileptics are often required to manage inflammatory reactions. May cause bone marrow suppression; obtain CBC at baseline and periodically. Dose adjustment not needed in renal impairment but caution in hepatic impairment.
Take this medication with a fatty meal (e.g., eggs, avocado, nuts) to improve absorption.,Do not crush or chew the tablets; swallow them whole with water.,Complete the full course of therapy even if you feel better.,Report any signs of liver problems: yellowing of skin/eyes, dark urine, severe nausea, or abdominal pain.,Avoid pregnancy during treatment and for at least 1 month after the last dose; use reliable contraception.,You may experience dizziness or blurred vision; avoid driving or operating machinery until you know how the drug affects you.,If you are breastfeeding, discuss with your doctor before taking this medication.
Take with a high-fat meal to increase absorption.,Complete the full course of therapy even if symptoms improve.,Use effective contraception during treatment and for at least 1 month after the last dose.,Report any signs of liver problems: yellowing of skin/eyes, dark urine, right upper quadrant pain.,May cause dizziness; avoid driving or operating machinery if affected.,Notify your healthcare provider if you experience persistent sore throat, fever, or unusual bleeding/bruising.
"Albendazole inhibits the CYP3A4-mediated metabolism of clemastine, leading to increased plasma concentrations of clemastine. This can potentiate the anticholinergic and sedative effects of clemastine, including dry mouth, urinary retention, constipation, and drowsiness. Patients may experience heightened central nervous system depression, especially with concurrent use of other CNS depressants."
"Ranolazine, a piperazine derivative antianginal agent, is a moderate CYP3A4 inhibitor. Albendazole is primarily metabolized by CYP3A4 to its active metabolite, albendazole sulfoxide. Coadministration increases albendazole systemic exposure by approximately 50%, potentially enhancing both therapeutic efficacy and dose-dependent toxicities, including hepatotoxicity and bone marrow suppression."
"Albendazole inhibits CYP3A4, the enzyme primarily responsible for the metabolism of lovastatin. This inhibition reduces lovastatin clearance, leading to elevated plasma concentrations and increased risk of statin-related adverse effects such as myopathy, rhabdomyolysis, and hepatotoxicity. Patients receiving this combination should be monitored closely for signs of muscle pain or weakness and liver enzyme abnormalities."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALBENDAZOLE vs ALBENZA, answered by our medical review team.
ALBENDAZOLE is a Anthelmintic that works by Albendazole inhibits tubulin polymerization by binding to beta-tubulin, disrupting microtubule formation, which leads to impaired glucose uptake and depletion of glycogen stores in susceptible parasites, resulting in their immobilization and death.. ALBENZA is a Anthelmintic that works by Albendazole is a benzimidazole carbamate that inhibits tubulin polymerization by binding to the colchicine site of β-tubulin, disrupting microtubule formation. This leads to impaired uptake of glucose and depletion of glycogen stores, resulting in immobilization and death of susceptible helminths.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALBENDAZOLE and ALBENZA depend on the specific clinical indication. These are both Anthelmintic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALBENDAZOLE is: 400 mg orally twice daily for 3-7 days for most indications; for neurocysticercosis, 400 mg orally twice daily for 8-30 days; for hydatid disease, 400 mg orally twice daily for 28-day cycles with 14-day drug-free intervals for 3 cycles.. The standard adult dose of ALBENZA is: 400 mg orally twice daily for 60 days for neurocysticercosis; 400 mg orally once daily for 3 days for pinworm; 400 mg orally once daily for 3 days for hookworm, roundworm, whipworm; 400 mg orally twice daily for 3 days for tapeworms; 400 mg orally twice daily for 7 days for giardiasis.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALBENDAZOLE and ALBENZA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALBENDAZOLE is classified as Category D/X. FDA Category C. First trimester: risk of skeletal abnormalities and embryotoxicity based on animal studies. Second and third trimesters: limited human data, but potential for fetal. ALBENZA is classified as Category C. Albendazole is contraindicated in pregnancy, especially during the first trimester. It has been shown to be embryotoxic and teratogenic in animals. In humans, there are reports of . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.